Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer

Claus Kamby; Simon Tarp; Anders Mellemgaard; Robin Christensen; Søren Cold; Pia Eiken; Erik Hugger Jakobsen; Niels Christian Langkilde; Sven Tyge Langkjer; Torben Laursen; Svend Saalbach Ottesen; Anita Gorm Pedersen; Lars Eric Stenbygaard; Peter Michael Vestlev

Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer

Claus Kamby, Simon Tarp, Anders Mellemgaard, Robin Christensen, Søren Cold, Pia Eiken, Erik Hugger Jakobsen, Niels Christian Langkilde, Sven Tyge Langkjer, Torben Laursen, Svend Saalbach Ottesen, Anita Gorm Pedersen, Lars Eric Stenbygaard, Peter Michael Vestlev

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

This article is based on a systematic literature search and meta-analyses of clinical data regarding effects of bisphosphonates (BP) and denosumab (DS) on preventing skeletal related events (SRE) in patients with bone metastases from solid tumours. Although there are pharmacological differences between the different types of BP no major differences were observed between BP in preventing SRE or in adverse events. Treatment with DS has in three randomised trials showed a greater effect than BP in preventing SRE. The optimal choice of bone-anti-resorptive agent should depend on the patient's general condition, renal function and treatment logistics.

Bidragets oversatte titel	Prevention of skeletal related events in patients with bone metastases from solid tumours.
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	176
Udgave nummer	7
Sider (fra-til)	645-648
ISSN	0041-5782
Status	Udgivet - 30 mar. 2015

Citationsformater

@article{c71de3be3f914bb1a8b4943801ebd06a,

title = "Forebyggelse af skeletrelaterede h{\ae}ndelser hos patienter med knoglemetastaser ved solide tumorer",

abstract = "This article is based on a systematic literature search and meta-analyses of clinical data regarding effects of bisphosphonates (BP) and denosumab (DS) on preventing skeletal related events (SRE) in patients with bone metastases from solid tumours. Although there are pharmacological differences between the different types of BP no major differences were observed between BP in preventing SRE or in adverse events. Treatment with DS has in three randomised trials showed a greater effect than BP in preventing SRE. The optimal choice of bone-anti-resorptive agent should depend on the patient's general condition, renal function and treatment logistics.",

author = "Claus Kamby and Simon Tarp and Anders Mellemgaard and Robin Christensen and S{\o}ren Cold and Pia Eiken and Jakobsen, {Erik Hugger} and Langkilde, {Niels Christian} and Langkjer, {Sven Tyge} and Torben Laursen and Ottesen, {Svend Saalbach} and Pedersen, {Anita Gorm} and Stenbygaard, {Lars Eric} and Vestlev, {Peter Michael}",

year = "2015",

month = mar,

day = "30",

language = "Dansk",

volume = "176",

pages = "645--648",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "7",

}

TY - JOUR

T1 - Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer

AU - Kamby, Claus

AU - Tarp, Simon

AU - Mellemgaard, Anders

AU - Christensen, Robin

AU - Cold, Søren

AU - Eiken, Pia

AU - Jakobsen, Erik Hugger

AU - Langkilde, Niels Christian

AU - Langkjer, Sven Tyge

AU - Laursen, Torben

AU - Ottesen, Svend Saalbach

AU - Pedersen, Anita Gorm

AU - Stenbygaard, Lars Eric

AU - Vestlev, Peter Michael

PY - 2015/3/30

Y1 - 2015/3/30

N2 - This article is based on a systematic literature search and meta-analyses of clinical data regarding effects of bisphosphonates (BP) and denosumab (DS) on preventing skeletal related events (SRE) in patients with bone metastases from solid tumours. Although there are pharmacological differences between the different types of BP no major differences were observed between BP in preventing SRE or in adverse events. Treatment with DS has in three randomised trials showed a greater effect than BP in preventing SRE. The optimal choice of bone-anti-resorptive agent should depend on the patient's general condition, renal function and treatment logistics.

AB - This article is based on a systematic literature search and meta-analyses of clinical data regarding effects of bisphosphonates (BP) and denosumab (DS) on preventing skeletal related events (SRE) in patients with bone metastases from solid tumours. Although there are pharmacological differences between the different types of BP no major differences were observed between BP in preventing SRE or in adverse events. Treatment with DS has in three randomised trials showed a greater effect than BP in preventing SRE. The optimal choice of bone-anti-resorptive agent should depend on the patient's general condition, renal function and treatment logistics.

M3 - Tidsskriftartikel

C2 - 25350304

SN - 0041-5782

VL - 176

SP - 645

EP - 648

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 7

ER -